Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein chibby homolog 1 (CBY1) is a small, evolutionarily conserved protein that acts as a key "antagonist of β-catenin" and a negative regulator of canonical Wnt/β-catenin signaling[1][3][4][5][6]. CBY1 exerts its function by binding directly to the C-terminal region of β-catenin, inhibiting its interaction with Tcf/Lef transcription factors, and thereby repressing β-catenin-mediated transcriptional activity[1][2][4][5]. CBY1 also forms a complex with β-catenin and 14-3-3 proteins, promoting β-catenin's nuclear export and further decreasing its transcriptional activation. In addition to its role in Wnt signaling, CBY1 is important for cellular differentiation—especially in adipogenesis and cardiomyocyte development—and is essential for ciliogenesis through its localization and function at centrioles and basal bodies[1][7]. Loss or downregulation of CBY1, through genetic mutation or promoter hypermethylation, leads to enhanced Wnt/β-catenin signaling and has been implicated in the pathogenesis of various cancers (including chronic myeloid leukemia, colorectal, gastric, and laryngeal carcinomas) as well as in ciliopathy syndromes such as Joubert syndrome[1][2][4]. Currently, CBY1 itself is not a direct therapeutic target for approved drugs, but its expression/status serves as a mechanistic marker for aberrant Wnt/β-catenin signaling in disease contexts[2][4][7].
Negative regulation of β-catenin-mediated transcription by direct binding to β-catenin's C-terminal region, preventing interaction with Tcf/Lef transcription factors; Formation of a tripartite complex with β-catenin and 14-3-3 proteins, facilitating β-catenin nuclear export and reducing nuclear activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein chibby homolog 1 (CBY1).